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Background. Guidelines for treating anemia in dialysis pa-
tients accept, as high-end range of serum ferritin useful to opti-
mize erythropoietin therapy, values high as 500 to 900 lg/L, on
the hypothesis that ferritin might be not representative of iron
overload.
Methods. A superconducting quantum interference device
(SQUID) was used to make direct noninvasive magnetic mea-
surements of nonheme hepatic iron content in 40 dialysis pa-
tients treated with intravenous iron, and liver iron content was
compared with biochemical markers of iron status.
Results. Only 12/40 (30%) patients showed normal hep-
atic iron content (SQUID <400 lg/g), while 32.5% had mild
(400 to 1000 lg/g) and 37.5% severe (>1000 lg/g) iron over-
load, although 28/40 patients (70%) had serum ferritin below
500 lg/L. Among many parameters, hepatic iron content was
only correlated with ferritin (r = 0.324, P = 0.04). The receiver
operating characteristic (ROC) analysis showed the best speci-
ficity/sensitivity ratio to identify iron overload for ferritin
>340 lg/L (W = 0.716). Multivariate logistic regression analy-
sis demonstrated that an increase in serum ferritin of 100 lg/L
and female gender were independent variables associated with
moderate to severe hepatic iron overload: OR 1.71 (95% CI
1.10 to 2.67) and OR 10.68 (95% CI 1.81 to 63.15), respectively.
Conclusion. Hepatic iron overload is frequent in dialysis pa-
tients with ferritin below currently proposed high-end ranges,
and the diagnostic power of ferritin in indicating true iron
stores is better than presumed. Safety concerns should prompt
a reevaluation of acceptable iron parameters, focusing on po-
tential gender-specific differences, to avoid potentially harmful
iron overload in a majority of dialysis patients, mainly females.
The use of recombinant human erythropoietin
(rHuEPO) has made possible the correction of anemia
in most uremic patients [1–3]. As rHuEPO-stimulated
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erythropoiesis is very demanding, the successful use of
rHuEpo to correct anemia requires sufficient iron avail-
ability before and during therapy to allow an optimal drug
response [4–6]. As virtually all uremic patients on dial-
ysis on rHuEPO receive ongoing maintenance iron sup-
plementation in continuous or intermittent need-based
schedules, any associated risk (iron deficiency and iron
overload) must be weighted [7].
In the last years, a growing body of studies has eval-
uated the reliability of “old” and “new” biochemical
parameters in interpreting the truth of the iron sta-
tus: circulating serum ferritin and transferrin saturation
(TSAT), the percentage of hypochromic red cells, reticu-
locyte hemoglobin content, soluble transferrin receptor,
and zinc protoporhyrin. However, iron deficiency status
seems now easier to be diagnosed than does iron over-
load status. In fact, not only the “new” markers of iron
available for erythropoiesis are early and sensitive tools
in diagnosing iron deficiency as perceived at the level of
bone marrow progenitors, but also an “old” parameter
such as serum ferritin is a more useful gauge of iron sta-
tus at lower values than at higher ones. At a serum ferritin
concentration ≤12 lg/L, a status of true iron deficiency
may be comfortably forecasted. On the contrary, no alter-
native biochemical parameters other than serum ferritin
have been introduced to look for iron overload, and ulti-
mate validation of this parameter may only be drawn by
invasive techniques measuring directly tissue iron con-
tent, such as bone marrow or liver biopsy.
In fact, true tissue iron overload may lead to increased
serum ferritin really signaling increased iron stores, but
other reasons might account for neoplasia, inflammatory
or infectious state (serum ferritin being an acute-phase
reactant) and tissue damage (for instance liver disease)
with cellular lysis and release of tissue ferritin in the blood
stream. Inflammatory cytokines may block iron into tis-
sue stores, preventing bone marrow progenitors from us-
ing existing wealthy iron stocks, or may increase the rate
of secretion of serum ferritin in the blood stream, even in
the presence of empty iron stores, so that this circulating
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ferritin will eventually be not representative of stored
iron. In both cases, laboratory parameters might show a
dissociation between increased serum ferritin concentra-
tion and signaling of iron insufficiency from bone marrow
progenitors. As uremia is regarded as an inflammatory
status, it has been suggested that high serum ferritin
concentrations in uremic patients do not represent high
iron stores available for erythropoiesis, but belong to the
above-mentioned categories [8–11].
Most guidelines for treating anemia in uremic patients
on rHuEPO agree on the low-end range of serum ferritin
at which rHuEPO has to be started, but disagree on high-
end range, which has not to be exceeded to avoid risk
of iron toxicity. Values as high as 800 and 1000 lg/L had
been accepted [12], but lower values (500 lg/L) have been
recommended [13, 14].
Lights to clarify this important issue may only come
from measurements of tissue iron content, but invasive
techniques cannot be proposed for clinical sequential
studies.
We measured the liver iron concentration by in vivo de-
termination of hepatic magnetic susceptibility by SQUID
(superconducting quantum interference device) biosus-
ceptometer. The SQUID is predominantly determined
by the magnetic volume susceptibility of the paramag-
netic ferritin/hemosiderin iron in the liver. It has been
validated in comparison to percutaneous liver biopsy and
is the only noninvasive method yielding results that are
quantitatively equivalent to and that can be used inter-
changeably with those obtained by chemical analysis of
biopsy tissue [15–23].
The aim of our work was to verify hepatic iron stores
in uremic patients on dialysis as measured by the SQUID
and to validate the reliability of biochemical parameters
markers of iron status, thanks to their correspondence
with the hepatic nonheme iron content measured by the
SQUID.
METHODS
As SQUID is very expensive, a maximum of 50 eval-
uations was allowed for this research. Out of 40 patients
on chronic hemodialysis from at least 6 months at our
Self-Care Dialysis Center, 30 were eligible for this study
and agreed to participate. Another 10 patients were re-
cruited from the 60 patients on hemodialysis since at least
6 months at our Hospital Dialysis Center. The last 10 al-
lowed evaluations by SQUID were reserved in order to
have the possibility of performing a sequential control
over time in 10 cases.
Exclusion criteria were presence of overt inflamma-
tory and infectious disease, recent major bleeding, hospi-
talization, surgery, poor compliance, recent transfusions,
malignancies, steel plates, artificial joints, and cardiac
pacemakers (because of contamination of the magnetic
field employed by the SQUID). Informed consent was
obtained from all the patients.
In agreement with the European and Italian Guide-
lines for anemia in hemodialysis patients, current treat-
ment schedules in our center were the following: target,
hemoglobin 10 to 11 g/dL; TSAT 20% to 50%, and serum
ferritin 200 to 500 lg/L, respectively; monitoring, hemat-
ocrit testing every week and hemoglobin every 3 months,
iron testing every 3 months, sampled after 1 week after a
dose; iron therapy, continuous supplementation by intra-
venous sodium ferric gluconate complex 31.25 mg (“Fer-
lixit” 62.5 mg/amp) (Nattermann & Cie GmbH, Colonia,
Germany) dissolved in saline 20 mL infused in 15 minutes
at the end of hemodialysis once or twice a week.
All 40 patients who entered the study (15 females and
25 males) had been treated with iron therapy. Ten were
on maintenance intravenous iron from at least 6 months
at the moment of the evaluation by SQUID, and 30 had
suspended iron therapy from at least 2 months follow-
ing 15 months of continuous supplementation, after last
iron tests showing serum ferritin value >500 lg/L. Dialy-
sis adequacy was serially measured by Kt/V and resulted
>1.2 in all patients. Nobody tested positive for hepati-
tis B surface antigen, while 14 patients tested positive
for anti-hepatitis C virus antibodies. Liver enzymes were
persistently normal in all the 40 patients of the study. Thir-
teen patients underwent vitamin C therapy (500 mg intra-
venous at the end of dialysis once a week) owing to serum
ascorbate value below the normal range (<2.5 mg/mL);
rHuEPO was administered in 34 out of 40 patients as sub-
cutaneous injection at the end of the hemodialysis session
in doses ranging from 1000 to 12,000 U/week.
Study design
Study 1. Cross-sectional study. All 40 patients un-
derwent the evaluation by SQUID without changing the
ongoing therapeutic schedules. Patients on continuous
iron replacement received iron dose 1 week before the
SQUID examination. All patients underwent blood sam-
pling for biochemical examination in the same day of the
SQUID analysis.
Following previous validation of measurements of
hepatic nonheme iron content by the SQUID, the pa-
tients were grouped in (1) normal hepatic iron content
(<400 lg/g wet weight); (2) mild iron overload (>400 <
1000 lg/g wet weight); (3) moderate iron overload
(>1000 < 2000 lg/g wet weight); and (4) severe iron over-
load (>2000 lg/g wet weight). This grouping was based
on Torino SQUID activity (Tristan Technologies, Inc.,
San Diego, CA, USA). Ninety-one normal adults (mean
age 46.2 ± 13.9 years, range 21.2 to 72.2 years) with nor-
mal iron parameters and negative for the main genetic
hemochromatosis mutations (C282Y and H63D) had a
mean hepatic iron content of 223 ± 125 lg/g wet weight
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(range 0 to 394 lg/g wet weight); 2011 adult patients with
various degree of iron overload from different patho-
logic conditions (thalassemias, hemoglobinopathies, ge-
netic hemochromatosis, liver diseases, chronic anemias,
malignancies) ranged from 407 to 9856 lg/g wet weight.
The limits for mild, moderate, and severe iron overload
have been chosen on our experience, in accordance with
the literature [16, 48].
For calculations, hepatic iron content >400 lg/g wet
weight was considered “excess iron,” and biochemical in-
direct iron parameters were evaluated for their diagnostic
power in recognizing excess iron.
Study 2. Longitudinal study. The 10 patients with the
highest iron content as evaluated by SQUID were chosen
to repeat a second SQUID examination 6 months later
after iron supplementation withdrawal.
Measurement of nonheme hepatic iron concentra-
tion by SQUID was accomplished as follows. Liver iron
concentrations were derivated from the specific ferritin
iron susceptibility. The Torino SQUID biosusceptometer
(Model 5700; Tristan Technologies, Inc.) is a three-
channel system. The “next generation” biosusceptome-
ter planned for Oakland and Torino has been designed
by Dr. R.F. (Hamburg), in collaboration with Dr. D. P.
and Dr. R.F. of Tristan Technologies, Inc. It differs in liq-
uid elium container (dewar) structure, coil design, water
bag size, and weight and software design from the Cleve-
land and Hamburg instruments. Specificity should be im-
proved by inclusion of an additional surface-sensitive de-
tector coil and sensitivity should be improved by develop-
ing a smaller dewar gap distance using an adjustable tail
design. Dr. R.F., working in collaboration with Dr. A.P.
and F.L. (Torino), Dr. D.P. and Dr. R.F. (Tristan Tech-
nologies, Inc.), and the Thalassemia Consortium are crit-
ically evaluating the engineering advances incorporated
into the “next generation” biosusceptometer utilizing the
large group of thalassemia and controls patients receiv-
ing simultaneous liver biopsies. The correlation between
the liver iron biopsy and data obtained from the spec-
troscopy measurement was highly significant (r = 0.982,
P < 0.00005, personal communication).
Effective magnetic biosusceptibility has been mea-
sured by a protocol developed and validated by
Dr. R.F. Those measurements involve (1) ultrasound as-
sessment of liver volume, optimal site for measurement,
and skin to liver surface distance; (2) susceptibility mea-
surement; and (3) computer analysis of data. The mean
iron concentration value was calculated from all selected
runs in both independent detector channels. SQUID pro-
cedures were performed as described elsewhere [24–27].
Biochemical parameters
Serum ferritin (normal value in our laboratory 25 to
340 lg/L for males and 15 to 150 lg/L for females) was
evaluated by immunofluorometric assay, iron and trans-
ferrin concentration by iron guanidine hydrochloride/
ferrozin assay, and by nephelometric assay, respectively.
TSAT was calculated by the formula: [iron (lg/dL)/
[transferrin (mg/dL) × 1.4]. Hematologic parameters,
including hypochromic erythrocytes and reticulocyte
hemoglobin content were measured by hematology
analyzer (ADVIA 120; Bayer Diagnostics, Colonia,
Germany). Erythrocytes with hemoglobin concentration
<28 g/dL were considered to be hypocromic and values
were expressed as percentage of total red blood cells.
The reticulocyte hemoglobin content was calculated by
the product of hemoglobin concentration and reticulo-
cyte volume and a value <32 pg/mL was considered ab-
normal, based on the mean of the normal population.
Soluble transferrin receptors (sTfR) were measured by
commercially available enzyme-linked immunosorbent
assay (ELISA) (R&D Systems, Inc., Minneapolis, MN,
USA) (normal range 8.7 to 28.2 mmol/L). C-reactive pro-
tein (CRP) was measured by the nephelometric method
(Dade Boehring, Mannheim, Germany) (normal value
<3 mg/L). Intra- and interassay variation coefficients for
all iron status laboratory indices were <5%. Iron pa-
rameters considered in the work were measured in a
nonsteady-state system, as the patients were actively us-
ing iron to produce red cells. For the calculation of the to-
tal body iron stores the following formula has been used:
[serum ferritin (lg/L) × 120 × kg/body weight] in agree-
ment with previous reports suggesting that, although 1
lg/L plasma ferritin in the normal adult is equal to 8 to
10 mg tissue iron stores, when comparing individuals of
differing body weight, the conversion to 120 lg/kg storage
iron is preferable [28].
HFE gene mutations: DNA study. The C282Y and
H63D mutations of HFE gene were investigated by two
specific and standardized kits, produced by the Vienna
Lab, and purchased by Nuclear Laser Medicine SRL Set-
tala (MI) Italy, as previously described [29].
For the calculations in this study, C282Y heterozygous,
H63D heterozygous, and H63D homozygous were all
considered as “HFE gene mutation.”
Statistics
All data are expressed as mean ± standard deviation
unless otherwise detailed. Differences between groups
were evaluated by nonparametric Mann-Whitney U test,
analysis of variance (ANOVA) test, and Bonferroni test
for the analysis of discrete and continuous variables, re-
spectively. To identify optimal test and threshold values
for predicting hepatic iron excess, receiver operating
characteristics (ROC) curve analysis was performed by
computing sensitivity and specificity of the different tests
at various cut-off levels. Sensitivity was defined as the per-
centage of patients with hepatic iron excess having a pos-
itive biochemical test (true positive) (TP) and specificity
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Table 1. Main clinical, biochemical, and tissue parameters of the patients divided according to hepatic nonheme iron concentrations as measured
by superconducting quantum-interference device (SQUID)
Nonheme iron stores
Overall Normal Mild overload Moderate overloada
(N = 40) (N = 12) (N = 13) (N = 15) P value
Age years 53 ± 14 (30–79) 53 ± 15 (31–79) 57 ± 14 (32–79) 51 ± 12 (30–70) 0.59
Gender males/females 25/15 11/1 9/4 5/10 0.007
Dialysis age months 116 ± 117 (10–402) 88 ± 96 (10–359) 74 ± 79 (19–276) 174 ± 140 (18–402) 0.04
Iron dose mg/kgb 11 ± 9 (4–47) 14 ± 13 (5–47) 10 ± 8 (4–35) 9 ± 4 (4–19) 0.37
EPO therapy % patients 85 75 92 87 0.47
EPO dose U/weekb 4765 ± 2965 4667 ± 3162 5417 ± 3528 4231 ± 2315 0.62
(1000–12,000) (2000–12,000) (1000–12,000) (2000–8000)
Anti-hepatitis C virus positive% 35 42 15 47 0.19
Vitamin C therapy % 33 17 46 33 0.29
C-reactive protein mg/L 6.2 ± 8.3 (1–49) 5 ± 4.7 (1–15) 9.3 ± 13.4 (2–49) 4.5 ± 3.1 (2–13) 0.28
Serum albumin g/dL 3.6 ± 0.3 (3–4.2) 3.5 ± 0.2 (3.1–3.7) 3.7 ± 0.4 (3–4.2) 3.6 ± 0.3 (3.1–4.2) 0.25
Hemoglobin g/dL 11.4 ± 1.7 (7–15.1) 11.8 ± 1.8 (10–15.1) 10.3 ± 1.8 (7–13.1) 12 ± 1.1 (10–14) 0.016
Ferritin lg/L 361 ± 224 (14–886) 245 ± 183 (14–561) 329 ± 174 (51–609) 482 ± 246 (101–886) 0.016
Serum iron lg/dL 73 ± 34 (22–190) 81 ± 47 (22–190) 65 ± 33 (28–126) 74 ± 21 (32–112) 0.49
Transferrin mg/dL 163 ± 33 (106–266) 176 ± 46 (124–266) 157 ± 28 (106–227) 157 ± 20 (128–194) 0.22
TSAT % 33 ± 15 (7–86) 34 ± 20 (7–86) 31 ± 15 (9–58) 34 ± 8 (17–44) 0.78
Hypo % 3.8 ± 8.3 (0–43) 8.3 ± 13.9 (0–43) 2.1 ± 3.1 (0.2–11) 1.7 ± 2.7 (0.1–11) 0.07
CHr pg 32.3 ± 2.9 (22.3–37.1) 31.5 ± 4.5 (22.3–37.1) 32.9 ± 2.3 (29.9–37) 32.3 ± 1.9 (27.8–34.6) 0.48
Soluble transferrin receptors mmol/L 23.4 ± 13.1 (9.4–85.9) 28.9 ± 20.9 (9.9–85.9) 20.7 ± 5 (14.3–30) 21.5 ± 8.7 (9.4–42.4) 0.23
Soluble transferrin receptors/log ferritin 4.8 ± 5.1 (1.5–32.5) 7.4 ± 8.7 (1.6–32.5) 3.8 ± 1.4 (2.2–7.6) 3.6 ± 1.5 (1.5–6.7) 0.11
HFE gene mutation % patientsc 25 42 23 13 0.24
SQUID lg/g wet weight 832 ± 653 (0–3198) 230 ± 130 (0–373) 630 ± 189 (402–951) 1488 ± 579 (1034–3198) 0.02
Iron stores gd 2.7 ± 1.6 (0.1–5.8) 1.9 ± 1.3 (0.1–3.5) 2.4 ± 1.2 (0.4–4.2) 3.5 ± 1.9 (0.8–5.8) 0.02
Abbreviations are: EPO, erythropoietin; TSAT, serum transferrin saturation; Hypo, hypochromic red cells; CHr, hemoglobin reticulocyte content.
Normal value <400 lg/g wet weight; mild overload 400 to 1000 lg/g wet weight; moderate overload >1000 lg/g wet weight.
aIncluded one patient with severe iron overload (>2000 lg/g wet weight); bMean value over the last 6 months; cPatients C282Y heterozygous, H63D heterozygous,
and H63D homozygous were all considered as “HFE gene mutation; ” dCalculated by the formula: serum ferritin × 120 lg × body weight (kg).
as the percentage of patients with hepatic normal iron
having a negative biochemical test (TN). Tests showed
discriminative ability when the area under the curve (W)
was significantly different from 0.5.
Odds ratio (OR) and 95% CI were estimated by uni-
variate and multivariate logistic regression model. A P
value < 0.05 was considered as statistically significant.
RESULTS
Baseline demographic characteristics
of the studied population
Seventy percent of the patients (28/40) had serum fer-
ritin values below the high-end normal range of the Eu-
ropean and Italian Guidelines (<500 lg/L), and only two
patients (5%) had levels higher than 650 lg/L (Table 1).
Nevertheless, only 12 (30%) patients had hepatic iron
stores within the normal range (<400 lg/g wet weight),
while a mild-to-severe hepatic iron overload was mea-
sured in the other 28 (70%): mild in 13 (32.5%), moderate
in 14 (35%), and severe in 1 patient (2.5%).
The group with moderate-to-severe iron overload was
not significantly different for frequency of subjects still
undergoing iron supplementation, total iron amount
infused in the last 6 months, anti-hepatitis C virus pos-
itivity, vitamin C therapy, CRP, serum albumin concen-
trations, and HFE gene mutations (Table 1). Conversely,
there was a significantly increased number of females,
longer duration of dialysis, and higher serum ferritin level.
Hemoglobin value was significantly lower in the group
with mild overload, but was similar in the two groups
with normal and highest iron content (Table 1).
The number of patients with TSAT <15% was 3/21
(14%) in the subgroup with serum ferritin <340 lg/mL
and 0/19 in the subgroup with serum ferritin >340 lg/mL.
Furthermore, in the subgroup of patients with SQUID
values below and above the high end of the normal range
(400 lg/g wet weight), the number of patients with TSAT
lower than 15% was 1/12 (8%) and 2/28 (7%), respec-
tively.
Correlation between biochemical parameters and
SQUID and within biochemical parameters
Among the biochemical parameters, only serum fer-
ritin showed a weak significant correlation with the hep-
atic nonheme iron concentrations as measured by the
SQUID (r = 0.325, P = 0.041). The amount of variance
explained by serum ferritin is about 10.5% (Fig. 1).
Negative correlations were found between ferritin and
TSAT, on one side, and all the makers of iron deficiency
at the level of bone marrow progenitors on the other side
(Table 2).
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Fig. 1. Correlation between serum ferritin concentration and hepatic
nonheme iron content as measured by the superconducting quantum
interference device (SQUID) (r = 0.325, P = 0.041).
ROC curve
Diagnostic power of serum ferritin and TSAT in sig-
nalling hepatic excess iron was calculated by a ROC
curve (Fig. 2). Serum ferritin (W = 0.761), unlike TSAT
(W = 0.446), showed discriminative ability. Serum ferritin
demonstrated a marginal utility, as none of the cut-off val-
ues had a high level of utility (both sensitivity and speci-
ficity >80%). The best threshold value to detect hepatic
excess iron was >340 lg/L, associated with 75% speci-
ficity and 57% sensitivity. When the cut-off level was
increased to a value of >450, >500, or >600 lg/L, the
specificity becomes 82%, 92%, and 100%, respectively.
Logistic regression analysis
Univariate logistic regression analysis showed that
serum ferritin, female gender, and dialysis vintage were
the only factors associated with mild and moderate to
severe hepatic iron overload (Table 3). A multivariate
logistic regression model, including gender and ferritin,
confirmed that serum ferritin >500 lg/L and female gen-
der were independent risk factors for moderate-to-severe
hepatic iron overload: OR 10.75 (95% CI 1.54 to 75.16)
and OR 10.47 (95% CI 1.81 to 60.73), respectively. Al-
though not reaching the level of statistical significance,
serum ferritin >340 lg/L was also an independent risk
factor for having moderate to severe iron overload: OR
5.27 (95% CI 0.57 to 48).
Additional studies showed that, in multivariate analy-
sis adjusted by sex, an increase of 100 lg/L of serum fer-
ritin was an independent risk factor for having mild (OR
1.68, 95% CI 1.03 to 2.75) and moderate-to-severe (OR
1.71, 95% CI 1.10 to 2.67) hepatic iron overload. Female
gender remained the highest risk factor: OR 15.31 (95%
CI 1.41 to 165) and OR 10.68 (95% CI 1.81 to 63.15),
respectively.
Study 2. Longitudinal study
In the 10 patients who were reevaluated by SQUID af-
ter 6 months without iron supplementation, there was
a significant decrease in hepatic iron concentrations
(1302 ± 746 lg/g wet weight to 654 ± 272 lg/g wet weight,
P < 0.01), as well as in serum ferritin levels (550 ± 197
lg/L to 442 ± 155 lg/L, P < 0.05).
DISCUSSION
Our study correlates for the first time in dialysis pa-
tients the indirect parameters that estimate the iron sta-
tus with a direct measurement of liver iron obtained by
the SQUID.
When we planned this study, we did not forecast these
results. In fact, in agreement with the guidelines, our pol-
icy in iron supplementation was not aggressive, and most
of our patients were expected to have normal hepatic iron
concentration. Surprisingly, in 70% of subjects who were
on low-dosage continuous intravenous iron supplemen-
tation (or had even stopped iron supplementation from
at least 2 months) and have moderately high serum fer-
ritin, there was evidence of excess iron in liver storage as
demonstrated by SQUID.
Notwithstanding theoretical doubts on reliability of
serum ferritin, our study first demonstrates that high
serum ferritin concentration is an independent predictor
for having overloaded hepatic iron stores in dialysis pa-
tients, in agreement with that reported in children with
transfusion siderosis [18, 30]. Furthermore, the risk of
having iron overload is increased already at serum fer-
ritin values >340 lg/L (the high-end normal range for
men in our laboratories). In fact, the poor efficiency of
high values of serum ferritin in the ROC curve was due
to the low sensitivity, but specificity was high. At a cut-off
level of 340 lg/L, poor efficiency means that also some
patients with serum ferritin <340 lg/L have hepatic ex-
cess iron, coupled with a majority of patients with serum
ferritin >340 lg/L. Therefore, even 340 lg/L as high end
range might be too high in order to completely exclude
iron overload.
The fact that hepatic iron was not related to the iron
amount received over the last 6 months might be ex-
plained by the different handling of supplemented iron
in different cases, due to different erythropoietic demand
and different loss. As it has been previously underscored,
iron parameters considered in this work were measured
in a nonsteady-state system. Our study does not confirm
that, at least in uremic patients on dialysis in good clini-
cal conditions and without clinically overt inflammation,
moderately high serum ferritin is “not representative”
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Table 2. Pearson correlation coefficients among all iron status markers considered in this study
Soluble
Soluble transferrin
transferrrin receptor/
SQUID Ferritin Iron Transferrin TSAT Hypo CHr receptor log ferritin
Ferritin r 0.325
P 0.041
Iron r –0.051 r 0.343
P 0.75 P 0.03
Transferrin r –0.179 r –0.295 r 0.137
P 0.27 P 0.06 P 0.4
TSAT r –0.017 r 0.421 – –
P 0.92 P 0.007 – –
Hypo r –0.189 r –0.401 r –0.363 r 0.163 r –0.388
P 0.24 P 0.01 P 0.021 P 0.32 P 0.013
CHr r –0.069 r 0.320 r 0.508 r –0.128 r 0.534 r –0.846
P 0.67 P 0.044 P 0.001 P 0.43 P < 0.001 P < 0.001
Soluble transferrin receptors r –0.100 r –0.385 r –0.442 r 0.392 r –0.529 r 0.661 r –0.667
P 0.54 P 0.014 P 0.004 P 0.012 P < 0.001 P < 0.001 P < 0.001
Soluble transferrin receptors/log r –0.187 – r –0.376 r 0.459 r –0.475 r 0.658 r –0.608 –
ferritin P 0.25 – P 0.017 P 0.002 P 0.002 P < 0.001 P < 0.001 –
Iron storesa r 0.366 – r 0.253 r –0.318 r 0.348 r –0.389 r 0.248 r –0.288 r –0.415
P 0.02 – P 0.12 P 0.046 P 0.028 P 0.013 P 0.12 P 0.07 P 0.008
Abbreviations are: SQUID, superconducting quantum interference device; TSAT, serum transferrin saturation.
Statistically significant P values are in bold (P < 0.05).
aCalculated by the formula: serum ferritin × 120 lg × body weight (kg).
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Fig. 2. Receiver operating characteristics (ROC) curve analysis per-
formed by computing sensitivity and specificity of serum ferritin for
predicting hepatic iron excess at various cut-off levels. Serum ferritin
showed discriminative ability. The best threshold value for serum fer-
ritin to detect hepatic excess iron was >340 lg/L, associated with 75%
specificity and 57% sensitivity. The area under the curve (W) is signifi-
cantly different from 0.5.
of iron overload, and therefore, that “moderately high
serum ferritin concentrations may not be a reliable in-
dication for withholding iron administration in uremic
patients” [31]. We cannot exclude that uremic inflamma-
tion may had enhanced hepatic iron uptake and, perhaps,
reduced iron release from hepatic stores, but excess iron
is present in hepatic stores, when serum ferritin is moder-
Table 3. Univariate logistic regression analysis evaluating the odds
ratios of various clinical and biochemical factors for having two
degrees (mild and moderate) of increased hepatic iron content
Mild hepatic Moderate to severe
non-heme iron hepatic nonheme
overload iron overload
(>400 < 1000 (>1000
Clinical and biochemical lg/g wet weight) lg/g wet weight)
factors OR (95% CI) OR (95% CI)
Gender (female) 11 (1.25–97) 8 (1.87–34.22)
Body weight kg 0.98 (0.92–1.05) 0.97 (0.91–1.04)
Dialysis vintage years (0.20–5.87) (0.48–45.55)
(>3 < 10 > 10)
1.50 (0.22–10.08) 11.20 (1.04–120.36)
Iron therapy mg/kg (0.41–11.30) (0.27–5.25)
(>7 < 10 > 10)
0.65 (0.11–3.41) 1.60 (0.29–8.73)
Serum ferritin lg/L (0.29–11.87) (0.50–20.3)
(>340 < 500 > 500)
8.25 (0.89–76.12) 8.50 (1.68–42.98)
HFE gene mutation 0.30 (0.06–1.36) 0.32 (0.05–1.80)
Hepatitis C virus seropositive 0.67 (0.16–2.67) 2.25 (0.59–8.57)
Vitamin C therapy 3.23 (0.59–17) 1.06 (0.27–4.15)
C-reactive protein 0.91 (0.23–3.58) 1.56 (0.42–5.72)
(>3 mg/dL)
Serum albumin (<3.5 g/dL) 0.4 (0.12–1.83) 0.72 (0.19–2.64)
ately high. However, our criteria inclusions for patients
excluded many types of chronic hemodialysis patients (in-
cluding “hospitalization, recent surgery and transfusions,
infectious diseases, malignancies”). These patients would
likely have higher ferritin, and therefore, further studies
are needed to clarify if our results may be applied also in
these cases.
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As to the clinical meaning of hepatic iron overload,
this topic was beyond the scope of our work. However,
many studies pointed to the fact that hepatic iron over-
load may predict more diffuse iron overload in other or-
gan and tissues [32], and focused on toxicity for immune
system [33–36], liver function [37–40], and cardiovascu-
lar system [41, 42], not only in thalassemia and genetic
hemochromatosis, but also in uremia. SQUID is able to
quantify accurately intracellular ferritin iron in organs,
without differentiation between reticuloendothelial sys-
tem and parenchymal cells. On the other side, it is also
true that in the liver the reticuloendothelial system is well
represented.
Another important point to be drawn from our results
is the crucial role of female gender in increasing the risk
of iron overload. The phrase “clinical guidelines ignore
gender differences” [43] strictly applies to guidelines for
optimizing iron therapy in treating anemia of uremic pa-
tients. The appropriate ferritin cut-off value to use for
defining iron deficiency in males and females is under
debate [44–47], and guidelines should not forget gender-
specific cut-off points to evaluate iron overload in ure-
mic people treated with rHuEPO, as the risk for having
iron storage overload is more than 10 times increased in
women in our study.
CONCLUSION
Thanks to a noninvasive procedure, just needing a low
field magnet to be placed over the liver, we may know the
true iron status for that concerns hepatic tissue stores in
dialysis patients chronically supplemented with mainte-
nance intravenous iron. We realize that, due to the cost
and lack of availability, SQUID will not be a useful tool
clinically for many patients. However, as “biomagnetic
susceptometry provides the only noninvasive method to
measure tissue iron stores that has been calibrated, vali-
dated, and used in clinical study” [23], we planned to have
use of the unique possibility offered from the SQUID in
our city in order to explore the vexing area of the relia-
bility of indirect parameters in indicating iron stores.
While all the other parameters of iron status (including
soluble transferrin receptors and hypochromic red cells)
lack any correlation, serum ferritin is validated as roughly
representative of hepatic iron store at least in hemodial-
ysis patients without overt inflammation. In these cases,
serum ferritin can be clinically used for the monitoring of
iron stores, and when its value exceeds 500 lg/L the risk
for having moderate to severe storage iron overload is 10
times increased (and further 10 times more in females)
independently from HFE gene mutations, CRP values,
and hepatitis C virus seropositivity.
Optimal correction of anemia would be facilitated by
more specific gender-tailored guidelines, but advocating
an aggressive approach to iron replacement in the hope of
improving anemia and maximize rHuEPO efficacy casts
some doubts on the potential intermediate and long-term
risks. Our data suggest that the high end ranges of serum
ferritin proposed from clinical guidelines for optimizing
iron therapy in uremic patients treated with rHuEPO
should be lowered, perhaps to those of the general pop-
ulation, at least in stable patients in good clinical condi-
tions. The feel that the goal of iron therapy is to optimize
rHuEPO efficacy and not the iron status is debatable, and
claims that clinicians do not need to be too alarmed by
high serum ferritin levels provoke worry.
Reprint requests to Dr. Caterina Canavese, Department of Nephrol-
ogy, S. Giovanni Molinette Hospital, Corso Bramante 88, 10126 Torino,
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